Evotec
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive res...
Latest News
8 months ago · seekingalpha.com
Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth TranscriptEvotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript
9 months ago · newsfilecorp.com
Moving iMage Transforms Eight Screen Santa Fe Theater Complex for EVO Entertainment with Cutting-Edge Laser Projection and Digital Sound Systems, including an EVX Enhanced Viewing Experience AuditoriumSanta Fe, New Mexico and Fountain Valley, California--(Newsfile Corp. - February 26, 2026) - Moving iMage Technologies, Inc. (NYSE American: MITQ), a leading provider of cutting-edge out-of-home entertainment technology and services for cinema, stadiums, arenas, Esports and other venues, today announced the completion of a substantial cinema technology consultation and auditorium upgrade for EVO Entertainment's new eight-screen theater complex in Sante Fe, New Mexico. The upgraded theater complex, which is the anchor tenant within the newly renovated San Isidro Plaza, opened doors to the public on Friday, January, 23rd 2026.
9 months ago · businesswire.com
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision CorrectionLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing.
9 months ago · businesswire.com
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic DermatitisPALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of an interleukin-18 (IL-18) binding protein and an anti-serum albumin Fab-associated domai.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove EVO